Clinical and pathological implications of IgG antibody responses to Helicobacter pylori and its virulence factors in non-ulcer dyspepsia

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 7, 2003, Pages 935-943

  Xia, H H X ^a   Talley, N J ^a   Blum, A L ^b   O'Morain, C A ^c   Stolte, M ^d   Bolling Sternevald, E ^e   Mitchell, H M ^f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c ADELAIDE AND MEATH HOSPITAL   (Ireland)

^d INSTITUTE OF PATHOLOGY   (Germany)

^e Linkoping Hospital   (Sweden)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIMOX; AMOXICILLIN; ANTIGEN VACA; BACTERIAL ANTIGEN; CAGA PROTEIN; CLARITHROMYCIN; IMMUNOGLOBULIN G ANTIBODY; OMEPRAZOLE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DRUG EFFECT; DYSPEPSIA; ERADICATION THERAPY; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; RISK FACTOR; SEROLOGY; STOMACH BIOPSY; SYMPTOM; TREATMENT OUTCOME; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-ULCER AGENTS; ANTIBODIES, BACTERIAL; DOUBLE-BLIND METHOD; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS;

EID: 0037392284     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01525.x     Document Type: Article

References (47)

1. Xia HH-X, Talley NJ. Helicobacter pylori eradication in patients with non-ulcer dyspepsia. Drugs 1999; 58: 785-92.
2. Holtmann C, Coebell H, Holtmann M, et al. Dyspepsia in healthy blood donors: pattern of symptoms and association with Helicobacter pylori. Dig Dis Sci 1994; 39: 1090-8.
3. Perri F, Clemente R, Festa V. et al. Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Am J Gastroenterol 1998; 93: 2082-8.
4. Gilvarry J, Buckley MJM, Beattie S. et al. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1997; 32: 535-40.
5. Greenberg PD, Cello JP. Lack of effect of treatment for Helicobacter pylori on symptoms of nonulcer dyspepsia. Arch Intern Med 1999; 159: 2283-8.
6. Blum AL, Talley NJ, O'Morain C. et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1875-81.
7. Talley NJ, Janssens J, Lauritsen K. et al. Cure of H. pylori in functional dyspepsia: a randomised double-blind placebo controlled trial with 12 months follow-up. Br Med J 1999; 318: 833-7.
8. McColl K, Murray L, El-Omar E. et al. Symptomatic benefits from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1869-74.
9. Talley NJ, Vakil N, Ballard IID, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999; 341: 1106-11.
10. Crabtree JE, Taylor JD, Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991; 338: 332-5.
11. Tee W, Lambert JR, Dwyer B. Cytotoxin production by Helicobacter pylori from patients with upper gastrointestinal tract diseases. J Clin Microbiol 1995; 33: 1203-5.
12. Pan Z-J, van der Hulst RWM, Feller M. et al. Equally high prevalence of infection with cagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol 1997; 35: 1344-7.
13. Sozzi M, Valentini M, Figura N, et al. Atrophic gastritis and intestinal metaplasia in Helicobacter pylori infection: the role of CagA status. Am J Gastroenterol 1998; 93: 375-9.
14. Fox JC, Correa P, Taylor NS, et al. High prevalence and persistence of cytotoxin-positive Helicobacter pylori strains in a population with high prevalence of atrophic gastritis. Am J Gastroenterol 1992; 87: 1554-60.
15. Eslick CD, Lim LL-Y, Byles JE, Xia HH-X, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999; 94: 2373-9.
16. Mitchell HM, Hazell SL, Li YY, Hu PJ, Serological response to specific Helicobacter pylori antigens: antibody against CagA antigen is not predictive of gastric cancer in a developing country. Am J Gastroenterol 1996; 91: 1785-8.
17. Chow W-H, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-9.
18. Yamaoka Y, Kodama T, Graham DY, Kashima K. Search for putative virulence factors of Helicobacter pylori: the low-molecular-weight (33-35 K) antigen. Dig Dis Sci 1998; 43: 1482-7.
19. Lamarque D, Gilbert T, Roudot-Thoraval F, Deforges L, Chaumette MT, Delchier JC. Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa. Eur J Gastroenterol Hepatol 1999; 11: 721-6.
20. Aucher P, Petit ML, Mannant PR, Pezennec L, Babin P, Fauchere JL. Use of immunoblot assay to define serum antibody patterns associated with Helicobacter pylori infection and with H. pylori-related ulcers. J Clin Microbiol 1998; 36: 931-6.
21. Holtmann G, Talley NJ, Mitchell H, Hazell S. Antibody response to specific H. pylori antigens in functional dyspepsia, duodenal ulcer disease, and health. Am J Gastroenterol 1998; 93: 1222-7.
22. Mitchell HM, Hazell SL, Bohane TD, Hu P, Chen M, Li YY. The prevalence of antibody to CagA in children is not a marker for specific disease. J Pediatr Gastroenterol Nutr 1999; 28: 71-5.
23. Junghard O, Lauritsen K, Talley NJ, Wiklund IK. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia. Eur J Surg 1998; 583(Suppl.): 106-11.
24. Dixon MF, Genta RM, Yardley JH, Correa P, and the participants in the International Workshop on the Histopathology of Gastritis, Houston, 1994. Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996; 20: 1161-81.
25. Xia HH-X, Kalantar JS, Ma Wyatt J, et al. High sensitivity and specificity of a laboratory-based serological test, pylori DTect ELISA, for detection of Helicobacter pylori infection. Diagn Microbiol Infect Dis 2000; 36: 69-74.
26. Elitsur Y, Neace C, Werthammer MC, Triest WE. Prevalence of CagA, VacA antibodies in symptomatic and asymptomatic children with Helicobacler pylori infection. Helicobacter 1999; 4: 100-5.
27. Shiesh S-C, Sheu B-S, Yang H-B, Tsao H-J, Lin X-Z. Serological response to lower-molecular-weight proteins of H. pylori is related to clinical outcome of H. pylori infection in Taiwan. Dig Dis Sci 2000; 45: 781-8.
28. Glupczynski Y, Van den Borre Goutier S, Butzler J-P, Burette A. Evaluation of Helicoblot 2.0 - a new commercial western blot test - for the serological diagnosis of Helicobacter pylori infection. Gut 1995; 37(Suppl. 1): A59(Abstract).
29. Figueiredo C, Quint W, Nouhan N, et al. Assessment of Helicobacter pylori vacA and cagA genotypes and host serological response. J Clin Microbiol 2001; 39: 1339-44.
30. Yamaoka Y, Kodama T, Graham DY, Kashima K. Comparison of four serological tests to determine CagA or VacA status of Helicobacter pylori strains. J Clin Microbiol 1998; 36: 3433-4.
31. De Giacomo C, Lisato L, Negrin R, Licardi G, Maggiore G, Serum immune response to Helicobacter pylori in children: epidemiologic and clinical applications. J Pediatr 1991; 119: 205-10.
32. Cutler A, Schubert A, Schubert T. Role of Helicobacter pylori serology in evaluating treatment success. Dig Dis Sci 1993; 38: 2262-6.
33. Thijs JC, van Zwet AA, Meyer BC, Berrelkamp RJP. Serology to monitor the efficacy of anti-Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1994; 6: 579-83.
34. Lerang F, Haug JB, Moum B, et al. Accuracy of IgG serology and other tests in confirming Helicobacter pylori eradication. Scand J Gastroenterol 1998; 33: 710-5.
35. Fradkin A, Yahav Y, Diver-Haber A, Weisselberg B, Jonas A. The value of anti-Helicobacter pylori IgG antibodies in establishing eradication of infection in children. Israel J Med Sci 1997; 33: 87-92.
36. Glupczynski Y, Burette A, Goossens H, DePrez C, Butzler JP. Effect of antimicrobial therapy on the specific serological response to Helicobacter pylori infection. Eur J Clin Microbiol Infect Dis 1992; 11: 583-8.
37. Ohkusa T, Takashimizu I, Fujiki K, et al. Changes in serum pepsinogen, gastrin, and immunoglobulin G antibody titers in Helicobacter pylori-positive gastric ulcer after eradication of infection. J Clin Gastroenterol 1997; 25: 317-22.
38. Ikewaki J, Nishizono A, Goto T, Fujioka T, Mifune K. Comparison of serum antibody titers to Helicobacter pylori lipopolysaccharides, CagA, VacA and partially purified cellular extracts in a Japanese population. Microbiol Immunol 2000; 44: 29-39.
39. Shirai Y, Wakatsuki Y, Kusumoto T, et al. Induction and maintenance of immune effector cells in the gastric tissue of mice orally immunized to Helicobacter pylori requires salivary glands. Gastroenterology 2000; 118: 749-9.
40. Lee A, Vaccines. Eur J Gastroenterol Hepatol 1999; 11(Suppl. 2): S75-9.
41. DiPetrillo MD, Tibbetts T, Kleanthous H, Killeen KP, Hohmann EL. Safety and imnmnogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999; 18: 449-59.
42. Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and inmmnogenic in Helicobacter pylori-infected adults. Gastroenterology 1999; 116: 804-12.
43. Kim SY, Doh HJ, Jang MH, Ha YJ, Chung SI, Park HJ. Oral immunization with Helicobacter pylor-loaded poly(D,L-lactideco-glycolide) nanoparticles. Helicobacter 1999; 4: 33-9.
44. Sutton P, Wilson J, Kosaka T, Wolowczuk I. Lee A. Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies. Immunol Cell Biol 2000; 78: 28-30.
45. Luzza F, Contaldo A, Imeneo M, et al. Testing for serum IgG antibodies to Helicobacter pylori cytotoxin-associated protein detects children with higher grades of gastric inflammation. J Pediatr Gastroenterol Nutr 1999; 29: 302-7.
46. Xia HH-X, Gallagher C, English L, et al. Comparison between McCoy cell line and Hela cell line for detecting Helicobacter pylori cytotoxicity: clinical and pathological relevance. Ital J Gastroenterol Hepatol 1999; 31: 663-8.
47. Cover TL, Cao P, Lind CD, Tham KT, Blaser MJ. Correlation between vacuolating production by Helicobacter pylori isolates in vitro and in vivo. Infect Immun 1993; 61: 5008-12.